Covered recipient · General Payments record
SARAH C FABRY
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2023
$832.32
- Reported across 88 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2023 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $192.47 | 11 |
By paying entity
PY2023 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $104.92 | 5 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $29.28 | 2 |
| Lilly USA, LLC | $16.91 | 1 |
| GlaxoSmithKline, LLC. | $15.15 | 1 |
| ABBVIE INC. | $13.17 | 1 |
| DEXCOM, INC. | $13.04 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2023 (11)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $13.17 | 09/28/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997224267 | CMS |
| Dexcom, Inc. | $13.04 | 07/12/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1054914189 | CMS |
| GlaxoSmithKline, LLC. | $15.15 | 09/20/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1003383583 | CMS |
| Lilly USA, LLC | $16.91 | 03/13/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1032297485 | CMS |
| Novartis Pharmaceuticals Corporation | $14.28 | 03/27/2023 | Food and Beverage | Undisputed | 01/23/2026 | 991526419 | CMS |
| Novartis Pharmaceuticals Corporation | $15.00 | 08/04/2023 | Food and Beverage | Undisputed | 01/23/2026 | 991526441 | CMS |
| Novo Nordisk Inc | $13.01 | 02/13/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1001675471 | CMS |
| Novo Nordisk Inc | $24.36 | 03/10/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1001675501 | CMS |
| Novo Nordisk Inc | $19.82 | 06/07/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1001675479 | CMS |
| Novo Nordisk Inc | $23.04 | 11/09/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1001675489 | CMS |
| Novo Nordisk Inc | $24.69 | 11/09/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1001675507 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023
- Generated from
- OP_DTL_GNRL_PGYR2023_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.